World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
59
Citations
13124
World Ranking
12487
National Ranking
5344

Robert C. Newton publication distribution in Biology and Biochemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Robert C. Newton sits on this spectrum.

47–56 publications: 8 scientists 57–66 publications: 35 scientists 67–76 publications: 106 scientists 77–86 publications: 231 scientists 87–96 publications: 414 scientists 97–106 publications: 546 scientists 107–116 publications: 704 scientists 117–126 publications: 849 scientists 127–136 publications: 980 scientists 137–146 publications: 942 scientists 147–156 publications: 969 scientists 157–166 publications: 950 scientists 167–176 publications: 951 scientists 177–186 publications: 915 scientists 187–196 publications: 787 scientists 197–206 publications: 841 scientists 207–216 publications: 735 scientists 217–226 publications: 709 scientists 227–236 publications: 651 scientists 237–246 publications: 605 scientists 247–256 publications: 510 scientists 257–266 publications: 524 scientists 267–276 publications: 434 scientists 277–286 publications: 418 scientists 287–296 publications: 350 scientists 297–306 publications: 363 scientists 307–316 publications: 315 scientists 317–326 publications: 296 scientists 327–336 publications: 261 scientists 337–346 publications: 240 scientists 347–356 publications: 219 scientists 357–366 publications: 197 scientists 367–376 publications: 154 scientists 377–386 publications: 161 scientists 387–396 publications: 155 scientists 397–406 publications: 145 scientists 407–416 publications: 124 scientists 417–426 publications: 112 scientists 427–436 publications: 132 scientists 437–446 publications: 116 scientists 447–456 publications: 99 scientists 457–466 publications: 81 scientists 467–476 publications: 91 scientists 477–486 publications: 80 scientists 487–496 publications: 80 scientists 497–506 publications: 60 scientists 507–516 publications: 36 scientists 517–526 publications: 46 scientists 527–536 publications: 54 scientists 537–546 publications: 44 scientists 547–556 publications: 43 scientists 557–566 publications: 43 scientists 567–576 publications: 42 scientists 577–586 publications: 25 scientists 587–596 publications: 34 scientists 597–606 publications: 23 scientists 607–616 publications: 33 scientists 617–626 publications: 31 scientists 627–636 publications: 27 scientists 637–646 publications: 25 scientists 647–656 publications: 28 scientists 657–666 publications: 34 scientists 667–676 publications: 18 scientists 677–686 publications: 16 scientists 687–696 publications: 10 scientists 697–706 publications: 12 scientists 707–716 publications: 21 scientists 717–726 publications: 12 scientists 727–736 publications: 12 scientists 737–746 publications: 10 scientists 747–756 publications: 7 scientists 757–766 publications: 13 scientists 767–776 publications: 15 scientists 777–786 publications: 13 scientists 787–796 publications: 9 scientists 797–806 publications: 9 scientists 807–816 publications: 7 scientists 817–826 publications: 4 scientists 827–836 publications: 9 scientists 837–846 publications: 7 scientists 847–856 publications: 3 scientists 857–866 publications: 5 scientists 867–876 publications: 5 scientists 877–886 publications: 11 scientists 887–896 publications: 3 scientists 897–906 publications: 4 scientists 907–916 publications: 7 scientists 917–926 publications: 5 scientists 927–936 publications: 6 scientists 937–946 publications: 6 scientists 947–956 publications: 3 scientists 957–966 publications: 7 scientists 967–976 publications: 2 scientists 977–986 publications: 2 scientists 987–996 publications: 1 scientists 997–1,006 publications: 5 scientists 1,007–1,016 publications: 2 scientists 1,017–1,026 publications: 2 scientists 1,027 publications: 1 scientists 1,028+ publications: 100 scientists
47 publications 1,028+

This scientist: 149 publications — 26th percentile

26% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,028 publications or more.

Robert C. Newton D-index placement in Biology and Biochemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Robert C. Newton sits on this spectrum.

40–41 D-Index: 80 scientists 42–43 D-Index: 183 scientists 44–45 D-Index: 317 scientists 46–47 D-Index: 504 scientists 48–49 D-Index: 718 scientists 50–51 D-Index: 900 scientists 52–53 D-Index: 1,026 scientists 54–55 D-Index: 1,150 scientists 56–57 D-Index: 1,236 scientists 58–59 D-Index: 1,253 scientists 60–61 D-Index: 1,163 scientists 62–63 D-Index: 1,131 scientists 64–65 D-Index: 1,032 scientists 66–67 D-Index: 897 scientists 68–69 D-Index: 814 scientists 70–71 D-Index: 715 scientists 72–73 D-Index: 709 scientists 74–75 D-Index: 596 scientists 76–77 D-Index: 512 scientists 78–79 D-Index: 473 scientists 80–81 D-Index: 412 scientists 82–83 D-Index: 373 scientists 84–85 D-Index: 358 scientists 86–87 D-Index: 285 scientists 88–89 D-Index: 273 scientists 90–91 D-Index: 227 scientists 92–93 D-Index: 208 scientists 94–95 D-Index: 193 scientists 96–97 D-Index: 153 scientists 98–99 D-Index: 157 scientists 100–101 D-Index: 148 scientists 102–103 D-Index: 120 scientists 104–105 D-Index: 113 scientists 106–107 D-Index: 100 scientists 108–109 D-Index: 86 scientists 110–111 D-Index: 67 scientists 112–113 D-Index: 72 scientists 114–115 D-Index: 73 scientists 116–117 D-Index: 64 scientists 118–119 D-Index: 53 scientists 120–121 D-Index: 60 scientists 122–123 D-Index: 54 scientists 124–125 D-Index: 43 scientists 126–127 D-Index: 38 scientists 128–129 D-Index: 49 scientists 130–131 D-Index: 26 scientists 132–133 D-Index: 18 scientists 134–135 D-Index: 23 scientists 136–137 D-Index: 32 scientists 138–139 D-Index: 32 scientists 140–141 D-Index: 27 scientists 142–143 D-Index: 19 scientists 144–145 D-Index: 22 scientists 146–147 D-Index: 12 scientists 148–149 D-Index: 16 scientists 150–151 D-Index: 14 scientists 152–153 D-Index: 10 scientists 154–155 D-Index: 13 scientists 156–157 D-Index: 10 scientists 158–159 D-Index: 7 scientists 160–161 D-Index: 9 scientists 162–163 D-Index: 13 scientists 164–165 D-Index: 4 scientists 166 D-Index: 4 scientists 167+ D-Index: 98 scientists
40 D-Index 167+

This scientist: 59 D-Index — 38th percentile

38% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 167 D-Index or more.

Overview

Robert C. Newton is affiliated with Incyte in the United States. Their research spans multiple disciplines within medicine and biochemistry, genetics, and molecular biology, with a primary focus on molecular biology, oncology, cancer research, immunology, and physiology.

The scientist has contributed extensively to several key topics, including:

  • NF-κB Signaling Pathways
  • Immune Response and Inflammation
  • Asthma and respiratory diseases
  • Cytokine Signaling Pathways and Interactions
  • Receptor Mechanisms and Signaling
  • Fibroblast Growth Factor Research
  • Estrogen and related hormone effects

Robert C. Newton has published research in various high-impact venues, notably:

  • The FASEB Journal
  • Journal of Pharmacology and Experimental Therapeutics
  • Journal of Biological Chemistry
  • Molecular Pharmacology
  • PLoS ONE

The following are examples of recent papers that illustrate the scope and focus of their research work:

  • Clinicogenomic Analysis of FGFR2 -Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib, 2020, Cancer Discovery
  • Repression of transcription by the glucocorticoid receptor: A parsimonious model for the genomics era, 2021, Journal of Biological Chemistry
  • Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase δ Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy, 2020, Journal of Pharmacology and Experimental Therapeutics
  • Genomic determinants implicated in the glucocorticoid-mediated induction of KLF9 in pulmonary epithelial cells, 2020, Journal of Biological Chemistry
  • Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases, 2020, European Journal of Pharmacology

Frequent collaborators appearing in Robert C. Newton's published work include Mahmoud Mostafa, Akanksha Bansal, Anthony N. Gerber, Andrew Thorne, and Richard Leigh. These collaborations suggest a multidisciplinary approach integrating molecular biology, pharmacology, and immunology.

Best Publications

  • Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins.

    M. D. Tortorella;T. C. Burn;M. A. Pratta;I. Abbaszade

  • Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8 + T cells directly within the tumor microenvironment

    Stefani Spranger;Holly K Koblish;Brendan Horton;Peggy A Scherle

  • Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity

    Xiangdong Liu;Niu Shin;Holly K. Koblish;Gengjie Yang

  • Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family.

    Ilgar Abbaszade;Rui-Qin Liu;Fude Yang;Stuart A. Rosenfeld

  • Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050

    Jordan S. Fridman;Peggy A. Scherle;Robert Collins;Timothy C. Burn

  • Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer

    Bin Bing S Zhou;Michael Peyton;Biao He;Changnian Liu

  • Aggrecan protects cartilage collagen from proteolytic cleavage.

    Michael A. Pratta;Wenqing Yao;Carl Decicco;Micky D. Tortorella

  • First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.

    Gregory L. Beatty;Peter J. O'Dwyer;Jason Clark;Jack G. Shi

  • Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

    Alireza Eghtedar;Srdan Verstovsek;Zeev Estrov;Jan Burger

  • Therapeutic Potential and Strategies for Inhibiting Tumor Necrosis Factor-α

    Robert C. Newton;Carl P. Decicco

  • Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344.

    Carrie M. Brodmerkel;Reid Huber;Maryanne Covington;Sharon Diamond

  • Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells.

    Phillip C.C. Liu;Xiangdong Liu;Yanlong Li;Maryanne Covington

  • Regulation of monocyte integrin expression by beta-family chemokines.

    Krishna Vaddi;R. C. Newton

  • Developing c-MET pathway inhibitors for cancer therapy: progress and challenges.

    Xiangdong Liu;Robert C. Newton;Peggy A. Scherle

  • A Novel Kinase Inhibitor, INCB28060, Blocks c-MET–Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3

    Xiangdong Liu;Qian Wang;Gengjie Yang;Cindy Marando

  • Targeting the c-MET signaling pathway for cancer therapy

    Xiangdong Liu;Wenqing Yao;Robert C Newton;Peggy A Scherle

  • Characterization of human aggrecanase 2 (ADAM-TS5): substrate specificity studies and comparison with aggrecanase 1 (ADAM-TS4).

    Micky D. Tortorella;Rui-Qin Liu;Timothy Burn;Robert C. Newton

  • Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib.

    Ian M. Silverman;Antoine Hollebecque;Luc Friboulet;Sherry Owens

  • Selective Inhibition of ADAM Metalloproteases as a Novel Approach for Modulating ErbB Pathways in Cancer

    Jordan S. Fridman;Eian Caulder;Michael Hansbury;Xiangdong Liu

  • Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-alpha.

    Percy H. Carter;Peggy A. Scherle;Jodi A. Muckelbauer;Matthew E. Voss

Frequent Co-Authors

Peggy Scherle
Peggy Scherle Incyte (United States)
Srdan Verstovsek
Srdan Verstovsek The University of Texas MD Anderson Cancer Center
Thomas F. Gajewski
Thomas F. Gajewski University of Chicago
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
George L. Trainor
George L. Trainor Bristol-Myers Squibb (Germany)
James W. Hodge
James W. Hodge National Institutes of Health
Jeffrey Schlom
Jeffrey Schlom National Institutes of Health
Zeev Estrov
Zeev Estrov The University of Texas MD Anderson Cancer Center
Farhad Ravandi
Farhad Ravandi The University of Texas MD Anderson Cancer Center
Jan A. Burger
Jan A. Burger The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Biology and Biochemistry in the USA opens doors to diverse careers, many of which intersect with healthcare and advanced research. Pursuing an online degree can be a flexible way to gain specialized knowledge and skills. For those interested in management, the cahme accreditation for mha programs ensures quality training for aspiring healthcare administrators.

If you’re aiming for advanced clinical expertise, a doctor of nursing practice offers leadership roles for nurses, while some programs don’t require in-person clinicals. Those interested in high-level research or academic careers may consider an online phd in healthcare management, equipping graduates to solve complex problems in healthcare systems.

Additionally, the pharmaceutical industry is closely aligned with both biology and biochemistry. An online pharmd allows you to advance as a pharmacist or researcher in drug development. Each of these pathways offers unique opportunities for those inspired by the life sciences to shape the future of health and medicine.

Best Scientists Citing Robert C. Newton

Trending Scientists

Recently Published Articles